oral tirzepatide fda approved eli lilly says next-gen obesity drug helps patients lose 28% of body weight F.D.A. Approves New Obesity Drug – Oral Tirzepatide FDA Status (2026):

10.1152/physrev.00013.2014 111

Semaglutide May Effectively Treat Non-Diabetic Nephropathy, Study Finds Ryan Livingston Connor Iapoce Key Takeaways Semaglutide may benefit overweight or obese non-diabetic patients with IgA nephropathy, reducing proteinuria and body weight

Semaglutide can lower blood glucose by improving insulin response, and fasting also naturally lowers blood glucose levels by depleting the bodys available energy stores

However, peripheral melanocortin receptors in adipose tissue, muscle, and liver also contribute to metabolic regulation, suggesting multi-tissue coordinated responses to melanocortin signaling

Each daily dose of 2 capsules provides 500 mg of vitamin C, or 625% of the Nutrient Reference Value (NRV)